The Role of ctDNA in Gastric Cancer.
Loading...
Embargo End Date
ICR Authors
Authors
Mencel, J
Slater, S
Cartwright, E
Starling, N
Slater, S
Cartwright, E
Starling, N
Document Type
Journal Article
Date
2022-10-18
Date Accepted
2022-10-13
Abstract
Circulating tumour DNA (ctDNA) has potential applications in gastric cancer (GC) with respect to screening, the detection of minimal residual disease (MRD) following curative surgery, and in the advanced disease setting for treatment decision making and therapeutic monitoring. It can provide a less invasive and convenient method to capture the tumoural genomic landscape compared to tissue-based next-generation DNA sequencing (NGS). In addition, ctDNA can potentially overcome the challenges of tumour heterogeneity seen with tissue-based NGS. Although the evidence for ctDNA in GC is evolving, its potential utility is far reaching and may shape the management of this disease in the future. This article will review the current and future applications of ctDNA in GC.
Citation
Cancers, 2022, 14 (20), pp. 5105 -
Source Title
Cancers
Publisher
MDPI
ISSN
2072-6694
eISSN
2072-6694
2072-6694
2072-6694